Beauty composition and application thereof

Abstract

The invention provides a cosmetic composition and application thereof.The cosmetic composition comprises Ectoine and succinyl glycan, the mass ratio of Ectoine to succinyl glycan is (6-50): 1, and the composition has a synergistic effect on improving the phagocytic ability of macrophages, so that waste removal of the skin can be further accelerated, and the skin quality is improved. Especially, substances which are generated by a corium layer and can cause pigment formation.

Description

Technical Field

[0001] The present application relates to the technical field of cosmetics, and in particular to a cosmetic composition for improving the phagocytic ability of macrophages and its use. Background Art

[0002] The cells that synthesize pigments in the skin are melanocytes, which are located in the basal layer of the epidermis and have dendritic protrusions. The cells contain melanin organelles called melanosomes that form, store and transport melanin. After the formation of melanosomes, they are transferred to the cytoplasm of keratinocytes and transported to the epidermis as keratinocytes differentiate, gradually appearing on the surface of the skin. However, excessive melanin in the skin can produce negative pigmentation. For example, acne and sensitive skin often cause skin inflammation. This process may cause cellular metabolic disorders and produce a large number of abnormal metabolic color products. When these abnormal products cannot be eliminated normally, pigmentation may form on the surface of the skin or even in the dermis, resulting in a dark skin color or spots, causing chloasma, freckles, age spots, etc., resulting in poor cosmetic results.

[0003] So far, the development of whitening agents has mainly focused on tyrosinase inhibition. For example, kojic acid, arbutin, ellagic acid, Energy signal Dexpanthenol W (PCE-DP), ascorbyl tetraisopalmitate, etc. However, these whitening agents aim to inhibit pigmentation and promote the renewal of the stratum corneum to eliminate the pigments already formed in the epidermis to achieve the whitening effect. For the melanin already formed, especially the melanin formed in the dermis, it is obviously insufficient to achieve the hypopigmentation effect only through the above-mentioned pathways. How to improve the skin's ability to remove waste by itself, thereby reducing its pigmentation under the skin, especially in the dermis, is still a technical problem to be solved in this field. Summary of the invention

[0004] To this end, the inventors of the present application discovered after in-depth research that both ectoine and succinoglycan have the effect of enhancing the phagocytic ability of macrophages, thereby helping the skin to remove waste, especially newly produced pigments or long-standing pigmentation in the dermis.

[0005] After further combining the two, it was found that the combination of succinoglycan with a specific structure and ectoine in a certain proportion can further enhance the phagocytic ability of macrophages, which is obviously beneficial for those who want to eliminate / reduce newly produced pigments or long-standing pigmentation in the dermis.

[0006] The specific technical solutions of this application are as follows:

[0007] 1. A cosmetic composition comprising ectoine and succinoglycan,

[0008] Among them, the mass ratio of ectoine to succinoglycan is 6 - 50:1,

[0009] The succinoglycan has an octasaccharide repeating unit, and the octasaccharide repeating unit is composed of glucose and galactose,

[0010] The octasaccharide repeating unit has non-glycuronic substituents, and the non-glycuronic substituents include succinyl groups and pyruvate groups, and do not include acetyl groups.

[0011] 2. The composition according to item 1, wherein the mass ratio of ectoine to succinoglycan is 9 - 40:1.

[0012] 3. The composition according to item 1, wherein the octasaccharide repeating unit is composed of 7 glucoses and 1 galactose.

[0013] 4. The composition according to item 1, wherein the octasaccharide repeating unit has 1 succinyl group and 1 pyruvate group.

[0014] 5. The composition according to item 1, wherein the succinoglycan is an extracellular polysaccharide secreted by Agrobacterium.

[0015] 6. Use of the composition according to any one of items 1 - 5 in enhancing the phagocytic ability of macrophages.

[0016] 7. According to the use described in item 6, the enhancement of the phagocytic ability of macrophages includes preventing or reducing skin pigmentation.

[0017] 8. Use of ectoine or succinoglycan in enhancing the phagocytic ability of macrophages.

[0018] 9. According to the use described in item 8, the enhancement of the phagocytic ability of macrophages includes preventing or reducing skin pigmentation.

[0019] Effects of the Invention

[0020] It is first discovered in this application that both ectoine and succinoglycan have the effect of enhancing the phagocytic ability of macrophages, thereby helping the skin to remove waste, especially substances that cause pigment formation in the dermis.

[0021] Furthermore, the composition provided in this application can produce a synergistic effect in enhancing the phagocytic ability of macrophages, thereby further accelerating the removal of waste by the skin, especially substances that cause pigment formation in the dermis.

[0022] Based on the above findings, the solution provided in this application can be used to eliminate / reduce newly formed pigments or long-existing pigmentation in the dermis. Brief Description of the Drawings

[0023] Figure 1 It is a bar graph of the relative phagocytosis index of macrophage units.

[0024] Figure 2 It is a bar graph of the change in the number of brown spots of the formula matrix and formulation examples on the 14th and 28th days relative to the 0th day. Detailed implementation manners

[0025] The present application will be described in detail below in conjunction with the described implementation manners. Although specific embodiments of the present application are shown, it should be understood that the present application can be implemented in various forms and should not be limited by the embodiments set forth herein. On the contrary, these embodiments are provided so that the present application can be more thoroughly understood and the scope of the present application can be completely conveyed to those skilled in the art.

[0026] It should be noted that in the specification and claims, certain terms are used to refer to specific components. Those skilled in the art should understand that technicians may use different nouns to refer to the same component. The specification and claims do not use the difference in nouns as a way to distinguish components, but use the difference in the functions of components as the criterion for distinction. As mentioned throughout the specification and claims, "comprising" or "including" is an open-ended term and should be interpreted as "including but not limited to". The subsequent description of the specification is a preferred implementation manner for implementing the present application, but the description is for the purpose of the general principles of the specification and is not used to limit the scope of the present application. The protection scope of the present application shall be determined by what is defined in the appended claims.

[0027] The present application provides a beauty composition, which comprises ectoine and succinoglycan,

[0028] wherein, the mass ratio of the ectoine to the succinoglycan is 6 - 50:1.

[0029] In some implementation manners, the mass ratio of the ectoine to the succinoglycan is 9 - 40:1.

[0030] For example, the mass ratio of the ectoine to the succinoglycan (m 依克多因 :m 琥珀酰聚糖) It can be 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1, 20:1, 21:1, 22:1, 23:1, 24:1, 25:1, 26:1, 27:1, 28:1, 29:1, 30:1, 31:1, 32:1, 33:1, 34:1, 35:1, 36:1, 37:1, 38:1, 39:1, 40:1, 41:1, 42:1, 43:1, 44:1, 45:1, 46:1, 47:1, 48:1, 49:1, 50:1, etc.

[0031] The inventors of the present application have found through research that both ectoin and succinoglycan have the effect of enhancing the phagocytic ability of macrophages, and combining ectoin and succinoglycan with a specific structure in a certain proportion has a synergistic effect in enhancing the phagocytic ability of macrophages.

[0032] Ectoin (also known as tetrahydromethylpyrimidine carboxylic acid) is an amino acid derivative, which has been proven to be an effective ingredient for repairing the skin barrier in existing literature. Its mechanism of action is to form a protective layer composed of water molecules in the skin, thereby strengthening and restoring cell functions, stabilizing the skin barrier, and restoring and regulating the water content.

[0033] Succinoglycan is an extracellular polysaccharide produced by rhizobia, agrobacteria or other soil bacteria. Its polysaccharide is composed of glucose and galactose, and may also have some non-sugar aldehyde substituents, including succinyl groups, pyruvate groups, acetyl groups, etc. It is used as a biofilm or adhesion substance by many microorganisms. It is used as a stabilizer, thickener or gelling agent in the food industry and cosmetics industry, and has good moisture retention and biocompatibility.

[0034] The weight-average molecular weight of succinoglycan can be 1,300 - 6,000,000 Da. Specifically, it can be 1,300 Da, 1,500 Da, 2,000 Da, 3,000 Da, 4,000 Da, 5,000 Da, 6,000 Da, 7,000 Da, 8,000 Da, 9,000 Da, 10,000 Da, 20,000 Da, 50,000 Da, 100,000 Da, 110,000 Da, 120,000 Da, 130,000 Da, 140,000 Da, 150,000 Da, 160,000 Da, 170,000 Da, 180,000 Da, 190,000 Da, 200,000 Da, 210,000 Da, 220,000 Da, 230,000 Da, 240,000 Da, 250,000 Da, 260,000 Da, 270,000 Da, 280,000 Da, 290,000 Da, 300,000 Da, 310,000 Da, 320,000 Da, 330,000 Da, 340,000 Da, 350,000 Da, 360,000 Da, 370,000 Da, 380,000 Da, 390,000 Da, 400,000 Da, 450,000 Da, 500,000 Da, 550,000 Da, 600,000 Da, etc. For the method of the weight-average molecular weight, those skilled in the art can use the conventional methods in the art for determination. For example, the molecular weight of polysaccharides can be determined by Gel Permeation Chromatography (GPC).

[0035] In the present application, succinoglycan has an octasaccharide repeating unit, the octasaccharide repeating unit is composed of glucose and galactose, the octasaccharide repeating unit has a non-glycuronic substituent, the non-glycuronic substituent includes succinyl and pyruvoyl, and does not include acetyl.

[0036] In some specific embodiments, the octasaccharide repeating unit is composed of 7 glucoses and 1 galactose.

[0037] In some specific embodiments, the octasaccharide repeating unit has 1 succinyl and 1 pyruvoyl.

[0038] In some specific embodiments, the octasaccharide repeating unit includes a main chain and a side chain, the main chain is composed of glucose and galactose, and the side chain is composed of glucose.

[0039] In some specific embodiments, the succinyl and pyruvoyl are linked to the side chain of the octasaccharide repeating unit.

[0040] In some specific embodiments, the pyruvyl group is linked to the terminal glucose residue of the octasaccharide repeating unit. Preferably, the pyruvyl group is linked to the terminal glucose residue of the octasaccharide repeating unit in an O-4 and O-6 manner. Preferably, the keto group (C=O) of the pyruvic acid reacts with the O-4 and O-6 hydroxyl groups of glucose, and one molecule of water is removed to form a cyclic ketal.

[0041] In some specific embodiments, the succinyl group is linked to the 7th sugar residue at the reducing end of the octasaccharide repeating unit.

[0042] In some specific embodiments, the branched chain of the octasaccharide repeating unit is linked to the 4th sugar residue at the reducing end of the octasaccharide repeating unit.

[0043] In some specific embodiments, the glucose is a β-D-glucose residue and the galactose is a β-D-galactose residue.

[0044] In some specific embodiments, the succinoglycan is an extracellular polysaccharide obtained by fermentation of Agrobacterium.

[0045] In some more specific embodiments, according to the existing literature reports, the succinoglycan can be obtained by fermentation of Agrobacterium sp. ZCC3656.

[0046] In the present application, the method for obtaining succinoglycan by fermentation of Agrobacterium is not limited in any way, and those skilled in the art can obtain it based on known methods.

[0047] In some specific embodiments, the succinoglycan is obtained by fermentation of Agrobacterium through the following method: inoculating the seed liquid of Agrobacterium sp. ZCC3656 into the fermentation medium, and performing dynamic culture at 27-37 °C. After the culture is completed, the extracellular polysaccharide is extracted. Among them, the components of the fermentation medium can be, for example, 10-40 g / L sucrose, 0.3-1 g / L potato leaching powder, 0-5 g / L sodium chloride, and pH 6-8. Preferably, during dynamic culture, the shaking speed of the shaker is 220-300 rpm. Preferably, the culture time is 40-72 hours. Preferably, the method for extracting the extracellular polysaccharide is: after the culture is completed, 2-4 times the volume of 95% ethanol is added to the fermentation medium, and the precipitated extracellular polysaccharide is collected by centrifugation.

[0048] The above-mentioned succinoglycan can also be obtained by commercial purchase.

[0049] In some specific embodiments, the structural formula of the succinoglycan is as follows:

[0050]

[0051] Among them, n is an integer from 1 to 4000.

[0052] For example, n can be 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900, 3000, 4000, etc.

[0053] The reducing end refers to the rightmost end of this structural formula.

[0054] In some specific embodiments, calculated by mass percentage in the composition, the ectoin is 0.01 - 7%; the succinoglycan is 0.002 - 5%.

[0055] More specifically, calculated by mass percentage in the composition, the ectoin can be 0.01%, 0.05%, 0.1%, 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, etc.;

[0056] More specifically, the succinoglycan can be 0.002%, 0.005%, 0.01%, 0.05%, 0.1%, 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, etc.

[0057] In some embodiments, the composition further includes a physiologically acceptable medium. In the present application, the physiologically acceptable medium such as solvents, emollients, thickeners, chelating agents, UV filters, antioxidants, emulsifiers, fillers, colorants, preservatives, fragrances, active agents such as humectants, anti - aging agents, whitening agents and / or their mixtures.

[0058] As solvents, for example, aqueous solvents, oily solvents, polyols, etc.

[0059] As emollients, for example, squalane, isocetane, polydimethylsiloxane, jojoba esters, etc.

[0060] As thickeners, for example, polyacrylate cross - polymer - 6, xanthan gum, polyacrylic acids, celluloses, bentonite, fatty alcohols, etc.

[0061] As a chelating agent, such as disodium ethylenediaminetetraacetate (EDTA-2Na), etc.

[0062] As a UV filter, such as benzophenone, 4-butylmethoxydibenzoylmethane, octocrylene, ethylhexyl methoxycinnamate, ethylhexyl salicylate, phenylbenzimidazole sulfonic acid or homosalate, etc.

[0063] As an antioxidant, such as sodium bisulfite, tocopheryl acetate, p-hydroxyacetophenone, BHT and BHA, etc.

[0064] As an emulsifier, such as anionic emulsifier, cationic emulsifier, amphoteric emulsifier, non-ionic emulsifier.

[0065] As a filler, such as silica, mica, kaolin, oxides of zinc and titanium from natural or synthetic sources; calcium carbonate, magnesium carbonate and magnesium bicarbonate; zinc stearate, magnesium stearate or lithium stearate, zinc laurate, magnesium myristate, etc.

[0066] As a colorant, such as iron oxide, carbon black, titanium dioxide, zinc oxide, carmine, carotene, chlorophyll, etc.

[0067] As a preservative, such as p-hydroxyacetophenone, phenoxyethanol, benzyl alcohol, benzoic acid, sorbic acid, imidazolidinyl urea, etc.

[0068] As a fragrance, such as citronellol, tricyclodecenyl acetate, etc.

[0069] As a humectant, such as mannitol, sodium hyaluronate, lactic acid, glycerol, allantoin, propylene glycol, etc.

[0070] As an anti-aging agent, such as betaine, butanediol, retinol and its derivatives, peptides, phytosterols, silybum marianum extract, etc.

[0071] As a skin whitening agent, such as niacinamide, arbutin, phenyl ethyl resorcinol, ascorbic acid and its derivatives, etc.

[0072] The present application provides the use of the above-mentioned composition in enhancing the phagocytic ability of macrophages.

[0073] In some embodiments, the enhancement of the phagocytic ability of macrophages includes preventing or reducing skin pigmentation.

[0074] The composition described in the present application combines ectoine and succinoglycan with a specific structure in a certain proportion, which can significantly enhance the phagocytic ability of macrophages, thereby reducing skin pigmentation, for example, used for alleviating chloasma, freckles, senile plaques, acne marks, scars, etc.

[0075] The present application provides a method for alleviating skin pigmentation, which includes applying the above-described composition to a population in need thereof.

[0076] In some embodiments, the above method is a non-therapeutic method.

[0077] In the present application, the patient has any one or more of the skin problems such as melasma, freckles, senile plaques, acne marks and / or scars.

[0078] The present application provides the use of ectoine or succinoglycan in enhancing the phagocytic ability of macrophages.

[0079] In some embodiments, enhancing the phagocytic ability of macrophages includes preventing or reducing skin pigmentation.

[0080] The descriptions of ectoine and succinoglycan are as described above.

[0081] Examples

[0082] The present application generally and / or specifically describes the materials and test methods used in the experiments. In the following examples, unless otherwise specifically stated, % represents wt%, that is, weight percentage. For reagents or instruments whose manufacturers are not indicated, they are all conventional reagent products that can be obtained through commercial purchase. The raw materials used in the examples are shown in Table 1, and the equipment used is shown in Table 2.

[0083] Table 1

[0084]

[0085] Table 2

[0086] Main Equipment Manufacturer & Model Laminar Flow Hood Suzhou Sujing Purification Technology Co., Ltd., SW-CJ-2D Inverted Microscope OLYMPUS, CKX53 Precision Electronic Balance OHAUS, CP214 CO2 Incubator Thermo, 3111 UV Lamp Therapy Instrument Keno Medical Instrument Equipment Co., Ltd., KN-4006BL1 Microplate Reader Tecan, SPARK Real-Time PCR Instrument BioRad, CFX Connect VISIA VISIA, serial number: V70003334, Canfield Scientific, Inc.

[0087] Example 1

[0088] 1. Solution preparation:

[0089] Prepare a complete culture medium solution: Mix DMEM basal culture medium, FBS fetal bovine serum, and PS double antibody solution in a mass ratio of 89:10:1 to obtain a complete culture medium solution.

[0090] Weigh Ectoine, succinoglycan-1 powder, succinoglycan-2 powder, and succinoglycan-3 powder, and dissolve them in the complete culture medium solution according to the formulation ratio in Table 3 to form test substance working solutions respectively.

[0091] Among them, the structural formula of succinoglycan-1 is as follows:

[0092]

[0093] The structural formula of succinoglycan-2 is shown as follows:

[0094]

[0095] The structural formula of succinoglycan-3 is shown as follows:

[0096]

[0097] 2. Cytological test:

[0098] Macrophages are a type of white blood cell that mainly participates in the human immune response. They are distributed in many tissues of the human body. In the skin tissue, they are mainly distributed in the dermis layer and are mainly responsible for clearing dead or damaged cells, foreign pathogens, and other harmful particles in the skin. There are articles reporting [1] that stimulating the phagocytic activity and internalization of macrophages can phagocytose melanosome granules to improve pigmentation.

[0099] [1]: Nakano S, Abe Y, Nakajima K, Sano S, Yamamoto O, Wakamatsu K, Ito S, Hayashi M, Suzuki T. Establishment of a mouse model for post-inflammatory hyperpigmentation. Pigment Cell Melanoma Res. 2021 Jan; 34(1): 101-110. doi: 10.1111 / pcmr.12911. Epub 2020 Jul 24. PMID: 32623834.

[0100] 1) Cell seeding: Seed human monocyte cells into a 6-well plate at a seeding density of 1×10 5 cells / well, add PMA (100 μg / mL), and culture at 37 °C in 5% CO2 for 24 h to prepare a monolayer of macrophages in a 96-well plate. Discard the cell supernatant.

[0101] 2) Drug administration: Group and administer drugs according to the test protocol in Table 3. Add complete medium containing the test substance working solution to the wells of the sample group, add 1 mL of sample to each well, and set 3 replicate wells for each group. After drug administration, place the 6-well plate in an incubator (37 °C, 5% CO2) and culture for 24 h.

[0102] 3) Cell collection: After culturing for 24 h, gently wash the cells 1-2 times with 1 mL / well of D'Hanks buffer, add 100 μL of culture medium containing 50 μg / mL neutral red, incubate at 37 °C in 5% CO2 for 3 hours, and collect the samples.

[0103] 4) Remove the neutral red culture medium, gently rinse the cells with D-Hanks 1-2 times, add 150 μL of neutral red desorption solution, mix well by vibration, measure the absorbance at 540 nm, and calculate the phagocytosis index;

[0104]

[0105] 3. Result statistical analysis:

[0106] The t-test statistical analysis was used for comparison between groups, with a confidence level of 95%. Among them, the pairwise statistical comparisons were represented by letters to indicate the differences between groups. If the results of two groups contain completely different letters, it means there are statistical differences; if they contain the same letters, it means there are no statistical differences. The results are shown in Table 3 and Figure 1 as shown, from Table 3 and Figure 1 it can be seen that the index of case8-11 is higher than that of case1-2, and there are statistical differences with both case1-2, indicating that the combination of case8-11 has a synergistic effect.

[0107] Table 3

[0108]

[0109]

[0110] Note: Mass ratio = ectoin / succinoglycan;

[0111] Unit relative phagocytosis index = total phagocytosis index ÷ cell count

[0112] Example 2

[0113] 1. Formulation preparation

[0114] According to the test plan (Table 4), prepare the test substance working solutions respectively, and divide the working solutions into 12 pressing bottles at 30 g / bottle, with 6 parallels for each formulation.

[0115] According to the formulation matrix, weigh 25 grams of butanediol, 5 grams of glycerol, 5 grams of betaine, 0.25 grams of disodium EDTA, 0.25 grams of sodium sulfite, 2.5 grams of polyacrylate cross-linked polymer-6, 2.5 grams of p-hydroxyacetophenone, 2.5 grams of hexylene glycol, and the balance is water. Stir and dissolve evenly to prepare 500 grams of formulation matrix.

[0116] According to Comparative Example - 1, weigh 25 grams of butanediol, 5 grams of glycerol, 5 grams of betaine, 0.25 grams of EDTA - 2Na, 0.25 grams of sodium sulfite, 2.5 grams of polyacrylate cross - linked polymer - 6, 2.5 grams of p - hydroxyacetophenone, 2.5 grams of hexylene glycol, 1.25 grams of ectoin, and the balance of water. Stir and dissolve evenly to prepare 500 grams of the formulation matrix.

[0117] According to Comparative Example - 2, weigh 25 grams of butanediol, 5 grams of glycerol, 5 grams of betaine, 0.25 grams of EDTA - 2Na, 0.25 grams of sodium sulfite, 2.5 grams of polyacrylate cross - linked polymer - 6, 2.5 grams of p - hydroxyacetophenone, 2.5 grams of hexylene glycol, 1.25 grams of succinoglycan - 1, and the balance of water. Stir and dissolve evenly to prepare 500 grams of the formulation matrix.

[0118] According to the formulation example, weigh 25 grams of butanediol, 5 grams of glycerol, 5 grams of betaine, 0.25 grams of EDTA - 2Na, 0.25 grams of sodium sulfite, 2.5 grams of polyacrylate cross - linked polymer - 6, 2.5 grams of p - hydroxyacetophenone, 2.5 grams of hexylene glycol, 1.2195 grams of ectoin, 0.0305 grams of succinoglycan - 1, and the balance of water. Stir and dissolve evenly to prepare 500 grams of the formulation example, and the proportions of various components are shown in Table 4.

[0119] Table 4

[0120]

[0121] 2. Human testing:

[0122] The VISIA skin tester uses ultraviolet light mode and polarized light mode to present the deep - layer melanin distribution, including potential unmanifested pigmentation, and highlights the pigments in the dermis layer, namely brown spots, also known as liver spots.

[0123] 1) Volunteer screening: Select 18 volunteers, with the selected age range being 22 - 30 years old and having no obvious scars on the face. And evenly divide all the volunteers into 3 groups.

[0124] 2) Administration: According to the test plan in Table 4, conduct left - right control administration. For the first group of volunteers: use the formulation matrix on the left face and the formulation example on the right face. For the second group of volunteers: use the formulation matrix on the left face and Comparative Example - 1 on the right face. For the third group of volunteers: use the formulation matrix on the left face and Comparative Example - 2 on the right face. Apply 2 pumps of the working solution to each half - face, and set up 6 parallel tests for each group. Use it once in the morning and once in the evening, continuously apply for 28 days, and complete the volunteer photography on the 0th day, 14th day, and 28th day of use;

[0125] 3) Data collection: Use the VISIA skin tester to take pictures of the volunteers' half - faces and record the data.

[0126] 3. Data processing and result statistical analysis:

[0127] The t-test statistical analysis was used for comparison between groups, with a confidence level of 95%. The results are shown in Table 5 and Figure 2 as follows.

[0128] Table 5

[0129]

[0130] As can be seen from Table 5 and Figure 2 it can be seen that there are significant differences in the number of brown spots of the volunteers using the formulation cases compared to the volunteers using the formulation matrix, Comparative Example - 1, and Comparative Example - 2, indicating that the formulation cases containing ectoin and succinoglycan - 1 can significantly reduce skin pigmentation.

[0131] As described above, it is only a preferred embodiment of the present application and not a limitation in other forms. Any person skilled in the art may use the disclosed technical content to make changes or modifications into equivalent embodiments with equivalent changes. However, any simple modification, equivalent change, and modification made to the above embodiments based on the technical essence of the present application without departing from the technical solution content of the present application still fall within the protection scope of the technical solution of the present application.

Claims

1. A beauty composition comprising ectoine and succinoglycan, Among them, wherein the mass ratio of ectoine to succinoglycan is 6 - 50:1, wherein the succinoglycan has an octasaccharide repeating unit composed of glucose and galactose, wherein the octasaccharide repeating unit has a non - uronic acid substituent, and the non - uronic acid substituent includes a succinyl group and a pyruvyl group and does not include an acetyl group.

2. The composition according to claim 1, wherein, The mass ratio of ectoine to succinoglycan is 9 - 40:

1.

3. The composition according to claim 1, wherein the octasaccharide repeating unit is composed of 7 glucoses and 1 galactose.

4. The composition according to claim 1, wherein the octasaccharide repeating unit has 1 succinyl group and 1 pyruvyl group.

5. The composition according to claim 1, wherein the succinoglycan is an extracellular polysaccharide secreted by Agrobacterium.

6. Use of the composition according to any one of claims 1 - 5 in enhancing the phagocytic ability of macrophages.

7. The use according to claim 6, wherein enhancing the phagocytic ability of macrophages includes preventing or reducing skin pigmentation.

8. Use of ectoine or succinoglycan in enhancing the phagocytic ability of macrophages.

9. The use according to claim 8, wherein enhancing the phagocytic ability of macrophages includes preventing or reducing skin pigmentation.

Images